Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mimedx Group Inc (NQ: MDXG )

8.000 +0.200 (+2.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 576,572
Open 7.770
Bid (Size) 8.000 (1)
Ask (Size) 8.350 (5)
Prev. Close 7.800
Today's Range 7.550 - 8.000
52wk Range 5.470 - 9.270
Shares Outstanding 111,946,829
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MDXG Stock Earnings: MiMedx Group Beats EPS, Beats Revenue for Q1 2024
MDXG stock results show that MiMedx Group beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Mizuho Maintains Buy Rating for MiMedx Group: Here's What You Need To Know
Via Benzinga

Performance

YTD
+1.65%
+1.65%
1 Month
+27.19%
+27.19%
3 Month
-0.50%
-0.50%
6 Month
+11.58%
+11.58%
1 Year
+37.22%
+37.22%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Recap: MiMedx Group Q4 Earnings
Via Benzinga
Get Rich Quick With These 3 Biotech Stocks to Buy Now
Via InvestorPlace
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors to Inquire About Securities Class Action Investigation - MDXG
Via NewMediaWire
Exposures Product Safety
MiMedx Group's Earnings: A Preview
Via Benzinga
MDXG LOSS ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages MiMedx Group, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – MDXG
From Rosen Law Firm
Via Business Wire
MIMEDX ALERT: Bragar Eagel & Squire, P.C. is Investigating MiMedx Group, Inc. on Behalf of MiMedx Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of MiMedx Group, Inc. (MDXG) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Rivian Automotive Reports Weak Delivery Figures, Joins JOYY, MiMedx Group And Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For October 30, 2023
Via Benzinga
Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
From MediWound Ltd.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
MiMedx Targets Profitability with Strategic Realignment, Suspends Knee Osteoarthritis Program Activities
Via Benzinga
MiMedx Group (NASDAQ: MDXG) Reports Q1 2023 Financial Results Showing 21.7% Sales Growth
Via Spotlight Growth
Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
BioStem Aims To Stay Ahead Of Competition Through Its Unique Processes And Versatile Offerings In Wound Healing
Via Benzinga
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
Via FinancialNewsMedia
Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.